BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qu S, Zhang X, Wu Y, Meng Y, Pan H, Fang Q, Hu L, Zhang J, Wang R, Wei L, Wu D. Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Front Oncol 2022;12:874473. [DOI: 10.3389/fonc.2022.874473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zeng H, Zhang D, Yang Z, Hu Z, Yang Z, Fu Y, Hou J, Ngai S, Wang J, Chen J, Hu D, Zhou Z, Chen M, Zhang Y, Pan Y. Cholesterol and C-reactive protein prognostic score predicted prognosis of immune checkpoint inhibitors based interventional therapies for intermediate-to-advanced hepatocellular carcinoma patients. Int Immunopharmacol 2023;115:109651. [PMID: 36638663 DOI: 10.1016/j.intimp.2022.109651] [Reference Citation Analysis]
2 Guo B, Zhou Y, Ouyang T, Liu Z, Xia F, Chen Q, Chen X, Xiao Z. TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: a case report.. [DOI: 10.21203/rs.3.rs-2221582/v1] [Reference Citation Analysis]
3 Yan J, Deng M, Kong S, Li T, Lei Z, Zhang L, Zhuang Y, He X, Wang H, Fan H, Guo Y. Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review. iLIVER 2022. [DOI: 10.1016/j.iliver.2022.10.001] [Reference Citation Analysis]
4 Guo P, Pi X, Gao F, Li Q, Li D, Feng W, Cao W. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study. Front Oncol 2022;12:945915. [DOI: 10.3389/fonc.2022.945915] [Reference Citation Analysis]
5 Sun L, Xu X, Meng F, Liu Q, Wang H, Li X, Li G, Chen F. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Front Oncol 2022;12:980214. [DOI: 10.3389/fonc.2022.980214] [Reference Citation Analysis]